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Knowing the incidence of invasive meningococcal disease 
(IMD) is essential for planning appropriate vaccination poli-
cies. However, IMD may be underestimated because of mis-
diagnosis or insufficiently sensitive laboratory methods. Us-
ing a national molecular surveillance register, we assessed 
the number of cases misdiagnosed and diagnoses obtained 
postmortem with real-time PCR (rPCR), and we compared 
sensitivity of rPCR versus culture-based testing. A total of 
222 IMD cases were identified: 11 (42%) of 26 fatal cases 
had been misdiagnosed or undiagnosed and were reclas-
sified as IMD after rPCR showed meningococcal DNA in 
all available specimens taken postmortem. Of the samples 
tested with both rPCR and culture, 58% were diagnosed by 
using rPCR alone. The underestimation factor associated 
with the use of culture alone was 3.28. In countries such 
as Italy, where rPCR is in limited use, IMD incidence may 
be largely underestimated; thus, assessments of benefits of 
meningococcal vaccination may be prone to error.
Neisseria meningitidis is the major etiologic agent of bacterial meningitis and one of the most important 
causes of invasive bacterial disease worldwide (1,2). The 
annual number of invasive meningococcal disease (IMD) 
cases is estimated to be at least 1.2 million, resulting in 
≈135,000 deaths (3). Meningococcal meningitis is the most 
common form of meningococcal disease, accounting for 
80%–85% of all reported cases of this illness. In nearly 
half of these cases, sepsis is also present. The remaining 
15%–20% of cases are sepsis only (1–3); however, in the 
elderly, N. meningitidis can also cause pneumonia (4).
In Italy, recent data show that IMD in children results in 
a death for ≈13% (7% 8% for meningitis and 20% for sep-
sis) of case-patients (5). Among survivors, 10%–30% have 
disabling, long-term sequelae such as seizures, motor im-
pairments, hydrocephalus, sensorineural hearing loss, men-
tal retardation, and cognitive and behavioral problems (2,6). 
IMD has a high economic and social impact, and a vac-
cination program could be useful in reducing incidence of 
disease. However, to gauge the value of vaccination through 
the use of health technology assessment (7), precise data 
on IMD incidence are needed. Furthermore, meningococ-
cal infection has a rapid and severe clinical progression and 
clinical signs and symptoms that are similar to severe inva-
sive infections caused by other pathogens. Consequently, a 
fast and sensitive method of diagnosis is needed to ensure 
that contacts of meningococcal disease patients receive ap-
propriate prophylaxis to prevent secondary cases. Standard 
diagnostic microbiology using culture-based methods is 
critical, enabling molecular characterization of isolates and 
providing information on antimicrobial drug resistance. 
However, culture-based methods are strictly dependent on 
viability of microorganisms. That characteristic may be a 
serious limiting factor, especially in patients who have a 
rapid fatal outcome or who have already undergone antimi-
crobial therapy (8). 
N. meningitidis is a fastidious pathogen that frequently 
undergoes autolysis, and its growth can be inhibited by a 
single dose of antimicrobial drug therapy, even in cases 
when the patient dies from the infection (9). Therefore, 
molecular tests such as real-time PCR (rPCR) are used 
alone or in combination with culture to diagnose IMD and 
determine the serogroup of the implicated pathogen (5,10). 
However, in countries where use of rPCR is limited, IMD 
may go undiagnosed. Failure to diagnose IMD is under-
mining prevention efforts and evaluation of IMD incidence 
and leads to underestimation of IMD and imprecise as-
sessments of the relative risks and benefits of vaccination. 
By using data from Italy’s national register for molecular 
surveillance of invasive bacterial disease, we attempted 
to identify factors contributing to the underestimation of 
IMD, including suddenly fatal cases and the use of differ-
ent diagnostic procedures.
Methods
Patients
Our study evaluated retrospectively all patients included in 
the molecular surveillance register during 2007–2014. The 
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register was started in 2006 and has been expanded since 
2007 with dedicated funds from Italy’s Center for Disease 
Control through a project titled “Improving Diagnosis of 
Invasive Bacterial Infection by Molecular Methods.” The 
project and, consequently, the register were initially fo-
cused on pediatric hospitals. All pediatric hospitals or pe-
diatric wards in general hospitals in Italy were invited to 
participate. Upon request by clinicians, samples obtained 
from adults were also accepted, tested, and included in 
the register, and the number of adults tested has increased 
over the years. Molecular surveillance was organized and 
is still active as a voluntary, nonmandatory surveillance. 
To be included in the register, at least 1 sample from each 
patient had to be analyzed by using rPCR, whereas use of a 
culture-based test was not an inclusion criterion. All clini-
cal and laboratory data were recorded.
Sample Collection and Testing
Samples of blood, cerebrospinal fluid (CSF), or other 
normally sterile fluids were obtained as soon as possible 
(in most cases, before start of treatment) from patients in 
whom, on the basis of clinical signs and symptoms, in-
vasive bacterial disease was suspected upon hospital ad-
mission. Samples were then sent for molecular testing to 
the reference center (Immunology and Infectious Disease 
Laboratory, Anna Meyer Children’s Hospital, Florence, 
Italy) by using a freepost parcel carrier service; samples 
were delivered by the following day and tested within 2 
hours after arrival. A report was produced and immediately 
sent back (by fax or email) to the sending hospital so that 
clinicians had the report within 24 hours after shipment of 
the sample. Samples for cultures were collected and sent 
to local laboratories in accordance with the hospitals’ own 
procedures. Sepsis was clinically suspected in the presence 
of previously described signs and confirmed by blood tests 
(11). Meningitis was clinically suspected in the presence 
of a compatible clinical syndrome and abnormal chemical 
test results (12). A case was considered to be confirmed 
in the presence of positive microbiologic tests (culture or 
molecular tests). Our study evaluated all patients included 
in the molecular surveillance register and was approved by 
the Institutional Review Board at Anna Meyer Children’s 
University Hospital.
Diagnostic Criteria
A diagnosis of laboratory-confirmed IMD was made if a 
patient’s samples were culture positive for N. meningiti-
dis, rPCR positive for the ctrA gene, or both, as described 
previously (5). If no increase in the fluorescent signal oc-
curred before the 40th cycle of amplification, the sample 
was assumed to be negative. All samples in which the ctrA 
gene was detected by rPCR were included in a serogroup-
ing analysis. The serogroups A, B, C, W, and Y (13) were 
identified by rPCR or endpoint PCR (for serogroups W and 
Y) by using appropriate primers and probes (Table 1).
Results
Samples Received and Diagnosis of  
Meningococcal Infection
Patients were selected from among 85 hospitals in 19 of 
Italy’s 20 regions. The only region that did not include any 
patients represents 0.2% of Italy’s population. Of 222 pa-
tients evaluated, 211 (95.0%) were tested during hospital-
ization and 11 (5.0%) were tested postmortem (Figure 1). 
At least 1 sample from each of the 222 patients included in 
the study was tested by rPCR. Because the reporting of a 
culture-based test (or lack of one) was welcome but not re-
quired for a case to be included in the register, samples for 
culture-based tests were not available for all patients, but 
at least 1 sample for culture-based tests was available for 
187 of the 211 hospitalized patients. No culture-based test 
was performed for the 11 patients whose IMD diagnosis 
was postmortem; instead, diagnosis was performed by us-
ing rPCR on autoptic specimens, including blood, CSF, and 
formalin-fixed tissue samples (e.g., kidney, adrenal gland, 
brain, and lung tissue).
Among the 222 patients with confirmed IMD, we 
found 171 (77.0%) meningitis cases (11 of which were 
associated with sepsis) and 51 (23.0%) sepsis cases. A total 
of 158 (71.2%) cases were found in the pediatric age group 
(0–18 years of age), and 64 (28.8%) cases were found in 
adults (>18 years of age) (Figure 2). Children <1 year of 
age had the highest number of cases (46/222; 20.7%). The 
male-to-female ratio was 121:101 (1.2).
The rPCR tests performed directly on normally sterile 
fluids (blood or CSF) were positive for all 222 patients, and 
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Table 1. Primers and probes used for Neisseria meningitidis serogrouping of isolates from samples from a national register for 
molecular surveillance of invasive bacterial disease, Italy, 2007–2014 
Target Gene Forward primer Reverse primer Probe 
N. meningitidis ctrA gctgcggtaggtggttcaa ttgtcgcggatttgcaacta FAM_cattgccacgtgtcagctgcacat_TAMRA 
Serogroup A sacB cccccagcatggctagattt agggcactttgtggcataattt FAM_accctaaaattcaatgggtatatcacga_TAMRA 
Serogroup B siaD B ttggacttggttaagctgacctaa gttgacaacatctccattttatcttacc FAM_ttagatatgacaaataaattgttacgtggg_TAMRA 
Serogroup C siaD C agggaaccgcaacctatgc cacaaaacgttgctcaaattttg FAM_ccactcttagaatcatttacatacaaaccc_TAMRA 
Serogroup W/Y siaD 
W/Y 
gctgataaattgttcttatggtctgaa cggcaccagaaccaatctct FAM_ttggaatcatgagcttttaccaaatccaaca_TAMRA 
Serogroup W* siaD cagaagtgagggatttccata cacaaccattttcattatagttactgt  
Serogroup Y* siaD ctcaaagcgaaggctttggtta ctgaagcgttttcattataattgctaa  
*Identified by using endpoint PCR. 
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rPCR enabled serogrouping in 218 (98.2%) cases (4 sam-
ples were not serogrouped because of insufficient sample 
material). Of the 218 samples that were serogrouped, 172 
(78.9%) were serogroup B, 29 (13.3%) were serogroup C, 
8 (3.7%) were serogroup W, and 8 (3.7%) were serogroup 
Y. No organisms from serogroup A were found.
During the study period (2007–2014), a total of 26 
deaths occurred among the 222 patients, resulting in a case-
fatality rate of 11.7%. Five (19.2%) deaths occurred in pa-
tients <1 year of age, 7 (26.9%) in patients 1–5 years of age, 
8 (30.8%) in patients 6–18 years of age, and 4 (15.4%) in 
adult patients. Case-fatality rates were 22.6% (14/62 cases) 
in patients admitted with a diagnosis of sepsis or meningitis 
and sepsis and 7.5% (12/160 cases) in patients admitted for 
meningitis but with no mention of sepsis at admission.
Misdiagnosis and Postmortem Diagnosis of IMD
Postmortem diagnosis of IMD was obtained in 11 (5.0%) 
of the 222 cases. In all 11 cases, culture-based tests were 
either negative or impossible to perform because the pa-
tient died before being admitted to the hospital. Eight of 
these cases had been diagnosed as sepsis of unknown origin 
(Table 2). Here we describe the clinical progression of the 
other 3 cases.
Case 1
A 20-year-old, previously healthy woman had sudden on-
set of high fever with chills and general malaise. The next 
day, her general condition rapidly deteriorated. She was 
then referred to the emergency department but died on the 
way to the hospital. A diagnosis of sudden death was made; 
no blood test was performed. A few years later, autoptic 
specimens (formalin-fixed lung, kidney, and adrenal gland 
tissue) were tested (for legal reasons) at the Immunology 
and Infectious Disease Laboratory of the Anna Meyer Chil-
dren’s Hospital by using rPCR; all specimens were found 
to be positive for N. meningitidis serogroup B.
Case 2
A 5-month-old male infant was found dead in his crib. In 
the preceding days, he had shown poor feeding and irrita-
bility. He was born from healthy, nonconsanguineous par-
ents at the end of a normal pregnancy. In accordance with 
the national diagnostic protocol for sudden infant death 
syndrome (SIDS), an autopsy was performed. Autoptic 
samples (i.e., formalin-fixed lung, kidney, brain, and adre-
nal gland tissue) for diagnosis of infectious diseases were 
immediately transferred to the Immunology and Infectious 
Disease Laboratory, where rPCR showed the presence of 
N. meningitidis serogroup C in all the specimens.
Case 3
A 17-year-old male adolescent was admitted to the hospital 
with fever, diarrhea, vomiting, purpuric rash, and lethargy, 
symptoms that had manifested suddenly during the preced-
ing 6 hours. He had a normal clinical history and a nor-
mal history of school attendance, and he had participated 
in sports. Blood tests performed on his arrival showed a 
high leukocyte count (>70,000 cells/μL) and a low platelet 
count (<38,000/mL). He died in the hospital 1 hour after 
his arrival. During the following days, all culture-based 
test results were negative, and a diagnosis of acute myeloid 
leukemia resulting in death was made. Three days after his 
death, a family member was admitted to the hospital with 
a similar clinical signs and symptoms. The pathologist in 
charge of postmortem examination for the first patient was 
immediately alerted so that an infectious disease diagnosis 
could be considered. The pathologist decided to send for-
malin-fixed tissue samples to the Immunology and Infec-
tious Disease Laboratory. Blood samples from the second 
patient were also sent, and rPCR results led to a diagnosis 
of N. meningitidis group C infection in both patients.
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Figure 1. Distribution of patients diagnosed with invasive 
meningococcal disease during hospitalization or postmortem 
evaluation, by test performed for Neisseria meningitidis (real-
time PCR [rPCR] or rPCR and culture), from a national register 
for molecular surveillance of invasive bacterial disease, Italy, 
2007–2014.
Figure 2. Age distribution of 222 patients diagnosed with 
invasive meningococcal disease from a national register for 
molecular surveillance of invasive bacterial disease, Italy, 
2007–2014.
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Standard Culture-Based Tests versus rPCR
A total of 116 blood samples were tested with rPCR, and 
107 blood samples were tested with culture (Table 3). 
Blood was positive for N. meningitidis in 104 (89.7%) of 
116 samples tested with rPCR and in 26 (24.3%) of 107 
samples tested with blood culture (odds ratio [OR] 27.0, 
95% CI 12.1–61.2; p<0.0001). One culture sample was re-
ported as contaminated with Streptococcus viridans.
A total of 162 CSF samples were tested with rPCR, 
and 90 CSF samples were tested with culture (Table 3). 
CSF was positive in 160 (98.8%) of 162 samples tested 
with rPCR and in 33 (36.7%) of 90 samples tested with 
CSF culture (OR 138.1, 95% CI 30.7–862.6; p<0.0001). 
One culture sample was reported as contaminated with S. 
epidermidis. Overall, by considering both kinds of sam-
ples, rPCR was shown to be 3.28 times more sensitive 
than culture.
All 12 patients whose blood samples were negative 
by rPCR had CSF samples that tested positive by rPCR. 
Among the 81 patients whose samples tested negative 
by blood culture, CSF culture was not performed for 22 
(27.2%); 18 (22.2%) had samples that tested positive by 
CSF culture and 41 (50.6%) had samples that tested nega-
tive by CSF culture.
The 2 patients whose CSF samples tested negative 
by rPCR had blood samples that tested positive by rPCR. 
Among the 57 patients whose samples tested negative by 
CSF culture, a blood culture was not performed for 14 
(24.6%); a blood culture tested positive for N. meningitidis 
for 4 (7.0%) and negative for 39 (68.4%).
Overall (including CSF and blood samples), rPCR en-
abled a correct diagnosis of IMD in all (100%) patients. 
On the other hand, culture enabled a correct diagnosis in 
only 29 (42.0%) of 69 patients for whom blood and CSF 
cultures were performed at admission.
To better compare the sensitivity of rPCR versus cul-
ture, we evaluated samples collected at the same time and 
tested by using both methods. Of the 63 patients who had 
samples that were simultaneously tested with blood culture 
and rPCR on blood, 53 (84.1%) had samples that tested 
positive by rPCR, whereas 17 (26.9%) had samples that 
tested positive by culture (OR 14.3, 95% CI 5.5–38.2; 
p<0.0001); 45 (71.4%) had samples that tested negative by 
culture. One of the 17 samples that tested positive by cul-
ture was reported as contaminated. No sample found nega-
tive by rPCR was found positive by culture. Use of rPCR 
on blood was 3.12 times more sensitive than blood culture.
Eighty-eight patients had samples that were simul-
taneously tested with CSF culture and rPCR on CSF: 86 
(97.7%) had samples that tested positive by rPCR, whereas 
338 (37.5%) had samples that tested positive by culture 
(OR 71.6, 95% CI 15.7–451.1; p<0.0001); 54 (61.4%) 
had samples that tested negative by culture. One of the 33 
samples that tested positive by culture was reported as con-
taminated. No sample found negative by rPCR was found 
positive by CSF culture, and rPCR on CSF was 2.61 times 
more sensitive than CSF culture.
Overall, N. meningitidis was identified only by rPCR 
in 36 of 63 blood samples and in 53 of 88 CSF samples. 
For enabling a laboratory diagnosis of IMD, rPCR was 
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Table 2. Description of 11 case-patients with postmortem diagnosis of invasive meningococcal disease included in a national register 
for molecular surveillance of invasive bacterial disease, Italy, 2007–2014* 
Patient 
no. Sex 
Age at 
death Preexisting disease 
Cause of missing or 
incorrect diagnosis 
First diagnosis of 
cause of death 
Culture 
result 
rPCR 
result† Serogroup 
1 F 20 y 
 
None Died before being admitted 
to hospital 
Sudden death Not 
performed 
Positive B 
2 M 5 mo 
 
None Died before being admitted 
to hospital 
SIDS Not 
performed 
Positive C 
3 M 17 y 
 
None Misdiagnosis: acute 
myeloid leukemia 
Acute myeloid 
leukemia 
Negative Positive C 
4 F 5 mo 
 
None Died before being admitted 
to hospital 
Sepsis Not 
performed 
Positive B 
5 M 6 y 
 
None Died <1 h after hospital 
admission 
Sepsis Not 
performed 
Positive Y 
6 F 11 mo 
 
None Died before being admitted 
to hospital 
Sepsis Not 
performed 
Positive C 
7 M 4 y 
 
None Died before being admitted 
to hospital 
Sepsis Not 
performed 
Positive B 
8 M 15 y 
 
Previous meningitis 
at age 5 y 
Negative culture-based 
tests 
Sepsis Negative Positive Y 
9 M 20 y 
 
Diabetes type I Negative culture-based 
tests 
Sepsis Negative Positive C 
10 M 13 y 
 
None Died at hospital admission Sepsis Not 
performed 
Positive C 
11 M 6 y 
 
None Died at hospital admission Sepsis Not 
performed 
Positive B 
*SIDSs, sudden infant death syndrome; rPCR, real-time PCR. 
†Of ctrA gene of Neisseria meningitidis. 
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significantly more sensitive than culture (Cohen’s Kappa 
0.59, OR 23.4, 95% CI 11.3–49.1; p<0.001).
Discussion
Our analysis of the national register for molecular sur-
veillance of bacterial disease in Italy showed that at least 
2 main factors cause underestimation of IMD: misdiag-
nosis and insufficiently sensitive laboratory methods. In 
the register, 3 deceased patients had previously had a dif-
ferent disease diagnosis (i.e., SIDS, acute myeloid leuke-
mia, sudden death); later, when biological samples were 
tested for N. meningitidis for other reasons (e.g., a legal 
trial or a secondary case), samples from the patients were 
found to be positive for the pathogen. The extent of mis-
diagnosis is difficult to quantify. Although misdiagnoses 
account for 1.4% in the national register, the actual per-
centage is probably much higher because only cases for 
which a clinical doubt occurred and samples were tested 
posthumously had a chance of being found positive for 
N. meningitidis. In the 3 cases described in this article, 
samples were retrieved and tested posthumously. How-
ever, in absence of those incidental situations, all 3 cases 
would have been misdiagnosed, thus contributing to the 
underestimation of IMD.
Among the 26 fatal cases, >40% were undiagnosed by 
standard culture-based methods, thus substantially contrib-
uting to the underestimation of IMD. In all undiagnosed 
cases, culture-based test results were either negative or not 
performed because sudden death attributable to N. menin-
gitidis infection occurred before the patients were admitted 
to the hospital or upon their arrival at the emergency depart-
ment. Whereas rPCR can be used for postmortem analysis 
of samples and enables diagnosis and serogrouping, cul-
ture-based methods are not useful in those situations; rPCR 
can be used with formalin-fixed tissue (14,15), as occurred 
with 2 of our patients, and even with bodies in advanced 
decomposition (16). Diagnoses of IMD is important for 
timely administration of prophylaxis to contacts and for 
limiting underestimation of cases. Therefore, rPCR should 
be considered as a fundamental tool. Moreover, molecular 
techniques offer the opportunity to identify the serogroup 
in culture-negative and fulminant cases. The ability to iden-
tify serogroups has important implications for vaccination 
programs. In fact, if fatalities were more often associated 
with a specific serogroup, a dedicated vaccination program 
could be planned. Moreover, molecular techniques enable 
the meningococcus to be molecularly characterized, which 
is important for planning and monitoring vaccination with 
subcapsular meningococcal vaccines.
We found that all tissues tested postmortem were posi-
tive for N. meningitidis by using rPCR. No specific kind of 
tissue seems to be better suited for diagnostic testing.
As for laboratory confirmation of IMD in nonfatal cas-
es, current data confirm what has been shown previously 
about meningococcal (5,17) and pneumococcal (18,19) in-
fections: rPCR is approximately 3 times more sensitive than 
culture in identifying meningococcal infection, regardless 
of the type of biologic sample used or the patients’ clini-
cal signs and symptoms. Consequently, in countries (as in 
Italy) where most hospitals use only standard culture-based 
methods for diagnosis of invasive bacterial infections, inci-
dence of IMD may be largely underestimated.
Testing with rPCR can enable etiologic diagnosis and 
serogrouping in culture-negative samples (19–21). There-
fore, most countries have included rPCR techniques in 
addition to culture-based tests in surveillance programs. 
The results are encouraging: in developed areas, such as 
England or Wales, the number of diagnoses made has more 
than doubled with the use of rPCR because 58% of cases 
were confirmed by rPCR alone (22). Our study shows that 
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Table 3. Distribution of rPCR and culture-based test results for Neisseria meningitidis for CSF and blood samples from a national 
register for molecular surveillance of invasive bacterial disease, Italy, 2007–2014* 
Type of sample 
No. samples/no. tested (%) 
Positive by rPCR Negative by rPCR Not tested by rPCR Total† 
CSF     
 Culture positive 33 0 0 33/90 (36.7) 
 Culture negative 55 2 0 57/90 (63.3) 
 Not tested with culture 72 0 0 0 
 Total 160/162 (98.8) 2/162 (1.2) 0 0 
Blood     
 Culture positive 16 0 10 26/107 (24.3) 
 Culture negative 37 10 34 81/107 (75.7) 
 Not tested with culture 51 2 0 0 
 Total 104/116 (89.7) 12/116 (10.3) 0 0 
Total, CSF or blood     
 Culture positive 49 0 10 59/197 (29.9) 
 Culture negative 92 12 34 138/197 (70.1) 
 Not tested with culture 123 2 0 0 
 Total 264/278 (95.0) 14/278 (5.0) 0 0 
*A total of 162 CSF samples were tested with rPCR, and 90 were tested with culture-based methods. A total of 116 blood samples were tested with rPCR, 
and 107 were tested with culture-based methods. CSF, cerebrospinal fluid; rPCR, real-time PCR. 
†Proportion of samples that were positive, negative, or not tested with culture-based methods. 
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in Italy, as in England and Wales, >50% of cases are con-
firmed by rPCR alone. The advantage is even greater in 
countries with fewer health resources, where laboratory 
results might be negatively influenced by inadequate trans-
port and storage of samples (23). Testing with rPCR has the 
additional advantage of providing results rapidly, enabling 
speedy initiation of prophylaxis of contacts, thus prevent-
ing secondary cases.
Other underestimation factors undoubtedly exist, and 
underreporting is surely one of the most important (24). 
Clinicians must be made aware that, besides curing pa-
tients, identifying and reporting the bacterial etiology are 
important for enabling a better understanding of the epide-
miology of meningococcal disease and implementation of 
appropriate public health interventions, such as vaccination 
programs or prophylaxis for contacts. Hospitals unable to 
offer local rPCR should be encouraged to duly and prompt-
ly collect samples for offsite testing.
In summary, IMD is largely underestimated in Italy 
because of misdiagnosis, limited use of molecularly based 
laboratory methods, and undernotification. Using molecu-
lar methods for diagnosis of IMD in all patients with clini-
cal evidence that results in a suspicion of N. meningitidis 
infection and for postmortem diagnoses can help reduce 
underestimation of IMD.
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